Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CHM-2101 CAR-T cells |
Synonyms | |
Therapy Description |
CHM-2101 CAR-T cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CDH17, which potentially induce toxicity in CDH17-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CHM-2101 CAR-T cells | CHM 2101|CHM2101 | CHM-2101 CAR-T cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CDH17, which potentially induce toxicity in CDH17-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06055439 | Phase Ib/II | CHM-2101 CAR-T cells | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Recruiting | USA | 0 |